Test Price
700 AED✅ Home Collection Available
17p (TP53) Deletion FISH Test for Multiple Myeloma & CLL – Dubai Healthcare City
Executive Summary & Core Metrics
Accuracy Guarantee:
99.9% Diagnostic Sensitivity – ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics:
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection for peripheral blood; bone marrow aspiration performed at accredited hospital facilities only.
Clinical Guidance:
Telephonic Post-Test Clinical Interpretation by Board-Certified Medical Geneticist.
Insurance & Billing:
Direct Billing Verification via WhatsApp: +971 54 548 8731
This assay detects loss of the TP53 tumour suppressor gene locus on chromosome 17p using fluorescence in-situ hybridization (FISH). It is a cornerstone for risk stratification in multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL), directly influencing therapy selection. Priced at 700 AED with a 3–4 day turnaround, the test is performed under strict DHA regulatory oversight at our Dubai Healthcare City laboratory.
Test Overview & Methodology
The 17p (TP53) Deletion FISH Test identifies loss of the TP53 tumour suppressor gene in bone marrow aspirate or peripheral blood, enabling risk-stratified therapy for multiple myeloma and chronic lymphocytic leukaemia. This 700 AED assay combines high-precision FISH methodology with a 3–4 day turnaround, supporting timely clinical decisions under DHA regulatory standards.
FISH uses fluorescent DNA probes that hybridize specifically to the TP53 locus on chromosome 17p. A minimum of 200 interphase nuclei are scored to determine the percentage of cells with a single 17p signal (indicating deletion). Results are reported as the percentage of abnormal nuclei with an interpretive threshold of ≥10% for CLL and ≥20% for MM, in accordance with international consensus guidelines.
| Parameter | Our Test (DHA-Compliant) | Closest Alternative (NGS Panel) |
|---|---|---|
| Methodology | FISH (Fluorescence In-Situ Hybridization) – gold standard for 17p deletion detection | Next-Generation Sequencing (NGS) – broader genomic profiling, often requires confirmation by FISH |
| Analytical Sensitivity | ≥ 99% for clonal deletions in ≥ 10% of interphase nuclei | Variable; may miss low-level mosaicism without high-depth sequencing |
| Turnaround Time | 3–4 working days | 7–14 days |
| Price (UAE) | 700 AED | 2,500–4,000 AED |
| Regulatory Compliance | DHA/MOHAP approved; ISO 9001:2015 accredited; compliant with Federal Law No. 2 of 2019 | May require additional bioinformatics validation; often not directly accredited for therapy selection |
* NGS panels are powerful complementary tools but cannot replace FISH for rapid, cost-effective TP53 deletion status in MM and CLL.
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics specialist, I recognize that 17p (TP53) deletion is one of the most powerful independent adverse prognostic markers in both multiple myeloma and CLL. The result must be integrated with the full clinical picture—including imaging, serum markers, and symptoms—to personalise treatment intensity. Never stop or adjust any anti-cancer medication based on this result alone; always consult your treating physician first.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory – Do Not Self-Adjust Therapy
Important: Do not discontinue or modify prescribed anti-neoplastic therapy, supportive drugs, or any other medication based on this test result without explicit instruction from your supervising physician. Self-adjustment can compromise disease control and may lead to adverse outcomes.
Exclusion Criteria & Emergency Red Flags
Criteria That Prevent Testing
- Absence of a valid UAE-licensed physician’s prescription with clear clinical indication.
- Routine screening in asymptomatic individuals (not recommended per DHA guidelines).
- Uncontrolled infection or acute haemodynamic instability that precludes bone marrow sampling.
- Inability to provide informed consent (including minors without guardian consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability).
Emergency Red Flags – Seek Immediate Medical Attention
- Severe, new-onset bone pain or pathological fracture.
- Unexplained fever (>38.5°C), chills, or night sweats.
- Sudden bleeding, bruising, or petechiae.
- Progressive fatigue, pallor, or shortness of breath.
- Confusion, neurological deficits, or hypercalcaemia symptoms (nausea, thirst, constipation).
Patient FAQ & Clinical Guidance
1. What is the clinical significance of detecting 17p (TP53) deletion in my blood or bone marrow?
The 17p (TP53) deletion is a high-risk genetic marker predicting aggressive disease, shorter remission, and resistance to standard chemotherapy in MM and CLL. In multiple myeloma, it classifies patients into a high-risk subgroup that may require intensified treatment protocols, proteasome inhibitors, or early transplant consideration. In CLL, TP53 disruption frequently indicates poor response to fludarabine-based regimens and guides the use of novel targeted agents. The result is not a diagnosis but a crucial piece of the risk-stratification puzzle.
2. How is the test performed and what sample do I need to provide?
A bone marrow aspirate or 5–10 mL of peripheral blood is analysed using fluorescent DNA probes that bind to the TP53 gene region in interphase cells. For multiple myeloma, a bone marrow sample is preferred because plasma cells are concentrated there; however, if a marrow sample is not feasible, peripheral blood can be used when circulating plasma cells or CLL lymphocytes are present. Our trained mobile phlebotomists perform peripheral blood collection in your home using strict cold-chain preservation. A doctor’s prescription is mandatory as per DHA regulations.
3. How quickly will I get my results and how should I use them?
Results are typically ready within 3–4 working days, presented as percentage of nuclei with 17p deletion and an interpretive report by our haematopathologist. The report will state whether a TP53 deletion was detected and its clinical significance relative to reference thresholds (≥10% for CLL, ≥20% for MM). You should immediately share the report with your oncologist, who will integrate it with other risk factors to decide if therapy escalation, de-escalation, or a clinical trial is warranted. Our team offers a complimentary telephonic consultation to help you understand the findings, but all treatment decisions remain with your prescribing doctor.
UAE Regulatory & Data Privacy Adherence
Your Data Protection & Clinical Safety Framework
- All patient data is processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring secure collection, storage, and transmission of your health information.
- Health data handling adheres to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, governing electronic health records and telemedicine practices.
- Patient safety and informed consent protocols are aligned with Federal Decree-Law No. 4 of 2016 on Medical Liability, which establishes your rights regarding medical interventions and diagnostic procedures.
- A valid physician’s prescription is compulsory. This test is not applicable for pre-surgical clearance, pregnancy screening, or travel health assessments.
- Sample type: Bone Marrow (preferred for MM) or 3–5 mL peripheral blood in EDTA (lavender top). No fasting required. Inform the phlebotomist of any anticoagulant therapy.
- For minors, written guardian consent is mandatory under Federal Decree-Law No. 4 of 2016.
Clinical & Logistical Metadata
| Test Name | 17p (TP53) Deletion FISH Test |
| Price (AED) | 700 AED |
| Turnaround Time | 3–4 working days |
| Sample Type / Matrix | Bone Marrow Aspirate or Peripheral Blood (EDTA) |
| Methodology Used | Fluorescence In-Situ Hybridization (FISH) |
| ICD-10-CM Code | C90.0, C91.1 |
| LOINC Code | 33729-6 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians